That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 million Danish ...

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...

The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post "for a period to support a smooth ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...

The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...